Products Categories
| CAS No.: | 9041-93-4 |
|---|---|
| Name: | Bleomycin sulfate |
| Article Data: | 7 |
| Molecular Structure: | |
|
|
|
| Formula: | C55H84N17O21S3.HSO4 |
| Molecular Weight: | 2927.17 |
| Synonyms: | Bleomycin sulfate [Bleomycins];Bleomycine [INN-French];Bleomycin, sulfate;Bleomycin sulfate (JP14/USP);Bleomycins;3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-1-[[(2S)-2-amino-2-carbamoyl-ethyl]amino]-2-carbamoyl-ethyl]-5-methyl-pyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(3H-imidazol-4-yl)propanoyl]amino]-3-hydroxy-2-methyl-pentanoyl]amino]-3-hydroxy-butanoyl]amino]ethyl]-1,3-thiazol-4-yl]1,3-thiazole-4-carbonyl]amino]propyl-dimethyl-sulfanium;Blexane;Bleomicin;Bleomycin,sulfate (salt);Bleomycin sulfate [USAN:JAN];Bleomycinsulfate;Blenoxane (TN);Bleomycinum [INN-Latin];Pingyangmyvin A2;Bleomicina [INN-Spanish]; |
| EINECS: | 232-925-2 |
| Melting Point: | 197oC (dec) |
| Solubility: | 20 mg/mL in water |
| Appearance: | white powder |
| Hazard Symbols: |
 T, Xi
|
| Risk Codes: | 46-40-36/37/38 |
| Safety: | 53-36/37-45-36-26 |
| PSA: | 1506.34000 |
| LogP: | -4.20880 |
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
- 926293-55-26-Bromo-2-methylpyridine-3-carboxaldehyde
- 911112-05-55-Iodo-3-(trifluoromethyl)-2-pyridinamine
- 95789-13-21,3,7-trimethylpurine-2,6-dione
- 956104-42-02-Bromo-5-nitro-3-(trifluoromethyl)pyridine
- 910247-97-11,2,3-Trimethylimidazolium dimethyl phosphate
- 945683-37-41-butyl-2,3-dimethylimidazolium octanesulfate
- 50-21-5Lactic acid
- 302-17-0Chloral hydrate
- 87-99-0Xylitol
- 745-65-3Prostaglandin E1
- 76-05-1Aceticacid, 2,2,2-trifluoro-
- 78281-72-8Nepafenac
- 54-31-9Furosemide
- 93-14-1Guaifenesin
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Consensus Reports
IARC Cancer Review: Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man 26 (1981),p. 97.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.
Specification
1. Introduction of Bleomycin sulfate
Bleomycin sulfate is one kind of white powder. It is soluble in water, methanol, slightly soluble in ethanol, practically insoluble in acetone, ethyl acetate, butyl acetate, ethyl ether. The Product Categories of this chemical is Active Pharmaceutical Ingredients; UVCBs-biological; Intermediates & Fine Chemicals; Pharmaceuticals. The Classification Code of Bleomycin sulfate is Antineoplastic; Drug / Therapeutic Agent; Human Data; Mutation data; Reproductive Effect; Tumor data.
2. Properties of Bleomycin sulfate
Physical properties about Bleomycin sulfate are:
(1)Storage Temp. 2-8 °C; (2)Water Solubility: 20 mg/mL; (3)H-Bond Donor: 21; (4)H-Bond Acceptor: 33; (5)Rotatable Bond Count: 36; (6)Tautomer Count: 1000; (7)Exact Mass: 1511.478534; (8)MonoIsotopic Mass: 1511.478534; (9)Topological Polar Surface Area: 705; (10)Heavy Atom Count: 101.
3. Structure Descriptors of Bleomycin sulfate
(1)Canonical SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-]
(2)InChIKey: WUIABRMSWOKTOF-OCBSMOPSSA-N
(3)Smiles: S([O-])(=O)(=O)O.O1[C@H](O[C@@H]2[C@@H](O[C@H]([C@H]([C@@H]2O)O)CO)O[C@@H]([C@@H](C(N[C@@H]([C@@H]([C@@H](C(N[C@@H](C(=O)NCCc2nc(c3nc(C(=O)NCCC[S+](C)C)cs3)cs2)[C@@H](O)C)=O)C)O)C)=O)NC(c2nc([C@@H](CC(=O)N)NC[C@@H](C(=O)N)N)nc(c2C)N)=O)c2nc[nH]c2)[C@H]([C@H]([C@@H](O)[C@H]1CO)OC(N)=O)O
(4)InChI: InChI=1S/C55H83N17O21S3.H2O4S/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6;1-5(2,3)4/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88);(H2,1,2,3,4)/t21?,22?,23?,24?,25?,29-,30+,34?,35?,36?,37+,38+,39-,40-,41?,42-,43-,53+,54-;/m0./s1
4. Toxicity of Bleomycin sulfate
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | LDLo | unreported | .286units/kg (.286units/kg) | LUNGS, THORAX, OR RESPIRATION: FIBROSIS (INTERSTITIAL) LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA | Southern Medical Journal. Vol. 80, Pg. 646, 1987. |
| mouse | LD50 | intraperitoneal | 210mg/kg (210mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 17, Pg. 455, 1975. | |
| mouse | LD50 | subcutaneous | 103mg/kg (103mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
| mouse | LDLo | intramuscular | 74mg/kg (74mg/kg) | BEHAVIORAL: ATAXIA | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
| rat | LD50 | intraperitoneal | 240mg/kg (240mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 7, Pg. 108, 1976. | |
| rat | LD50 | subcutaneous | 86mg/kg (86mg/kg) | SKIN AND APPENDAGES (SKIN): HAIR: OTHER GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
| rat | LDLo | intramuscular | 59mg/kg (59mg/kg) | BEHAVIORAL: ATAXIA | Japanese Journal of Antibiotics. Vol. 29, Pg. 894, 1976. |
| women | TDLo | parenteral | 20ug/kg (.02mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" LUNGS, THORAX, OR RESPIRATION: CYANOSIS | Arthritis and Rheumatism. Vol. 28, Pg. 459, 1985. |
Or:
| 1. | dnr-esc 20 µmol/L | MUREAV Mutation Research. 164 (1986),19. | ||
| 2. | hma-mus/esc 10 mg/kg | MUREAV Mutation Research. 164 (1986),19. | ||
| 3. | par-wmn TDLo:20 µg/kg:PUL,SKN | ARHEAW Arthritis and Rheumatism. 28 (1985),459. | ||
| 4. | ipr-rat LD50:240 mg/kg | IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. 7 (1976),108. | ||
| 5. | scu-rat LD50:86 mg/kg | JJANAX Japanese Journal of Antibiotics. 29 (1976),894. | ||
| 6. | ipr-mus LD50:210 mg/kg | YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. 17 (1975),455. | ||
| 7. | scu-mus LD50:103 mg/kg | JJANAX Japanese Journal of Antibiotics. 29 (1976),894. |
5. Safety information of Bleomycin sulfate
Hazard Codes:
T, 
Xi Risk Statements: 46-40-36/37/38
R46:May cause heritable genetic damage.
R40:Limited evidence of a carcinogenic effect.
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 53-36/37-45-36-26
S53:Avoid exposure - obtain special instructions before use.
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36:Wear suitable protective clothing.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany: 3
RTECS: EC5991990
F: 10
Poison by subcutaneous and intraperitoneal routes. Human systemic effects: cyanosis, allergic dermatitis. Questionable carcinogen with experimental carcinogenic data. An experimental teratogen. Other experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of SOx. See other bleomycin entries.
6. Uses of Bleomycin sulfate
Bleomycin sulfate (CAS NO.9041-93-4) is a group of related glycopeptide antibiotics. Bleomycin A2 is the main component of the bleomycin employed clinically.
7. Production of Bleomycin sulfate
The product is extracted from the Verticillium Streptomyces (Str.Verticillus) of the same antibiotics isolated from actinomycetes 72. The production process for the three fermentation medium as starch, glucose, soybean powder, yeast extract, corn syrup, sodium chloride, zinc sulfate, copper sulfate, potassium dihydrogen phosphate, fermentation process once every 8 hours complement glucose solution,control fermentation broth residual sugar in about 1%, to be pH rebound began 8h complement corn syrup, each supplement intake to 0.5%, the middle of bleomycin fermentation does not produce foam, and therefore do not need to add defoaming oil. The refining process of bleomycin in aqueous solution to dissociation into cationic characteristics, acrylic weakly acidic cation exchange resin for separation, mention limit phenylhydrazine thion azobenzene, in methanol solution as a chelating agent, or toThe hydrogen sulfide removal of copper ions, repeatedly precipitated with acetone, purified and then filtered, vacuum drying was finished.